Zimmer Biomet Holdings Inc (NYSE:ZBH) Given Average Rating of “Hold” by Analysts

Zimmer Biomet Holdings Inc (NYSE:ZBH) has been given an average recommendation of “Hold” by the twenty-five ratings firms that are covering the company, MarketBeat reports. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $131.24.

A number of analysts have recently issued reports on ZBH shares. TheStreet lowered Zimmer Biomet from a “b-” rating to a “c” rating in a research report on Friday, June 7th. Cantor Fitzgerald set a $135.00 target price on Zimmer Biomet and gave the stock a “buy” rating in a research report on Friday, April 26th. Needham & Company LLC lifted their target price on CoStar Group from $500.00 to $600.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Evercore ISI raised Zimmer Biomet from an “in-line” rating to an “outperform” rating and set a $145.00 target price on the stock in a research report on Monday, April 8th. Finally, Barclays boosted their price objective on Zimmer Biomet from $113.00 to $117.00 and gave the company an “underweight” rating in a report on Monday, April 15th.

Zimmer Biomet stock traded up $0.19 during midday trading on Tuesday, reaching $122.09. The stock had a trading volume of 1,099,400 shares, compared to its average volume of 1,216,543. Zimmer Biomet has a twelve month low of $96.99 and a twelve month high of $134.55. The stock has a market capitalization of $24.70 billion, a PE ratio of 15.98, a PEG ratio of 2.25 and a beta of 1.14. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.00 and a quick ratio of 0.97. The firm has a 50-day moving average price of $118.09.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Friday, April 26th. The medical equipment provider reported $1.87 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.86 by $0.01. Zimmer Biomet had a positive return on equity of 13.24% and a negative net margin of 3.90%. The firm had revenue of $1.98 billion for the quarter, compared to analysts’ expectations of $1.97 billion. During the same quarter last year, the firm earned $1.91 earnings per share. The firm’s revenue for the quarter was down 2.1% compared to the same quarter last year. Analysts predict that Zimmer Biomet will post 7.81 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 31st. Stockholders of record on Friday, June 28th will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Thursday, June 27th. This represents a $0.96 annualized dividend and a dividend yield of 0.79%. Zimmer Biomet’s dividend payout ratio is presently 12.57%.

In other news, insider Sang Yi sold 426 shares of the business’s stock in a transaction that occurred on Friday, May 24th. The stock was sold at an average price of $114.88, for a total transaction of $48,938.88. Following the completion of the transaction, the insider now directly owns 1,457 shares in the company, valued at $167,380.16. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.72% of the company’s stock.

Large investors have recently made changes to their positions in the stock. Lindbrook Capital LLC increased its holdings in shares of Zimmer Biomet by 207.6% in the first quarter. Lindbrook Capital LLC now owns 203 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 137 shares in the last quarter. Motco increased its holdings in shares of Zimmer Biomet by 86.2% in the first quarter. Motco now owns 216 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 100 shares in the last quarter. Pinnacle Bank bought a new position in shares of Zimmer Biomet in the fourth quarter valued at $45,000. Horan Capital Advisors LLC. bought a new position in shares of Zimmer Biomet in the first quarter valued at $51,000. Finally, FNY Investment Advisers LLC bought a new position in shares of Zimmer Biomet in the first quarter valued at $54,000. 88.69% of the stock is currently owned by hedge funds and other institutional investors.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Further Reading: What are the qualifications of a portfolio manager?

Analyst Recommendations for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.